Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Celični modeli nevrodegeneracije in nevrovnetja kot orodje predkliničnih raziskav : primer zaviralca katepsina X
Authors:ID Horvat, Selena (Author)
ID Pišlar, Anja (Author)
Files:.pdf PDF - Presentation file, download (2,68 MB)
MD5: A82A1A2BE6D665B063D2AFB5462E4068
 
Language:Slovenian
Typology:1.01 - Original Scientific Article
Organization:Logo SFD - Slovenian Pharmaceutical Society
Abstract:Nevrodegenerativne bolezni, kot sta Alzheimerjeva bolezen in Parkinsonova bolezen, so povezane s progresivno izgubo nevronov, pri čemer nevrovnetje deluje kot ključni pospeševalec degenerativnih procesov. V raziskavi smo vzpostavili in ovrednotili sklop celičnih modelov za ponovljivo posnemanje ključnih procesov nevrodegeneracije in nevrovnetja ter funkcionalno vrednotenje spojin vodnic. Vključili smo model Alzheimerjeve bolezni, model Parkinsonove bolezni in modele nevrovnetja v celicah glije, tj. mikrogliji, astrocitih in oligodendrocitih, ki pomembno sodelujejo pri vnetnih procesih v osrednjem živčevju. Na vzpostavljenih modelih smo ovrednotili spojino AMS36, zaviralec katepsina X, z obetavnim zaščitnim učinkom na poškodovane nevrone in protivnetnim delovanjem. V celičnih modelih smo spremljali spremembe celičnega fenotipa, izražanje specifičnih celičnih označevalcev, stopnjo celične poškodbe ter aktivacijo poti apoptoze. Rezultati so potrdili ustreznost vzpostavljenih modelov, kar se odraža v povzročeni poškodbi celic in vnetnem odzivu, ter pokazali, da AMS36 poveča preživetje celic, zmanjša kazalce apoptoze in ublaži vnetni odziv. Predstavljeni sklop modelov predstavlja uporabno predklinično platformo za usmerjeno vrednotenje kandidatnih učinkovin pri procesih nevro degeneracije in nevrovnetja.
Keywords:celični modeli, nevrodegeneracija, nevrovnetje, zaviralec katepsina X
Publication status:Published
Publication version:Version of Record
Publication date:01.05.2026
Year of publishing:2026
Number of pages:str. 91-101
Numbering:Letn. 77, št. 2
PID:20.500.12556/DiRROS-31033 New window
UDC:616.831-003.8+616-002
ISSN on article:2536-4316
COBISS.SI-ID:278573315 New window
Note:Opis vira z dne 19. 5. 2026; Nasl. z nasl. zaslona;
Publication date in DiRROS:10.07.2026
Views:76
Downloads:37
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Farmacevtski vestnik : strokovno glasilo slovenske farmacije
Publisher:Slovensko farmacevtsko društvo
ISSN:2536-4316
COBISS.SI-ID:288686336 New window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:01.01.2025

Secondary language

Language:English
Title:Cellular models of neurodegeneration and neuroinflammation as tools for preclinical research : the case of a cathepsinX inhibitor
Abstract:Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are associated with progressive neuronal loss, with neuroinflammation acting as a key driver that accelerates degeneration. In this study, we established and validated a set of cellular models to reproducibly mimic key aspects of neurodegeneration and neuroinflammation and to enable functional evaluation of lead compounds. The set included an Alzheimer’s disease model, a Parkinson’s disease model, and neuroinflammation models in glial cells, namely microglia, astrocytes, and oligodendrocytes, which play important roles in inflammatory processes in the central nervous system. Using these models, we evaluated AMS36, a cathepsin X inhibitor, with promising neuroprotective effects on injured neurons and anti-inflammatory activity. Across the established models, we monitored changes in cellular phenotype, expression of specific cellular markers, the extent of cellular injury, and activation of apoptotic pathways. The results confirmed the suitability of the models, reflected by induced cellular damage and an inflammatory response, and showed that AMS36 increases cell survival, reduces apoptotic markers, and attenuates the inflammatory response. The presented set of models provides a useful preclinical platform for targeted evaluation of candidate compounds in the context of neurodegeneration and neuroinflammation.
Keywords:cathepsin X inhibitor, cellular models, neurodegeneration, neuroinflammation


Back